previous compound ID: 2570 next compound
InChIKey: XEYBRNLFEZDVAW-ARSRFYASSA-N
SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O)O

biological descriptors:

CFTR relevance: unspecified

Category:
Influence on CFTR function unknown
Order of interaction unknown
subcellular compartment unknown

reference list:

ReferenceID: 53
"R Robert" "SD Macknight" "B Kus" "J Liao" "E Matthes" "J Goepp" "GW Carlile" "D Rotin" "JW Hanrahan" "DY Thomas"

chemical graph of compound 2570





CID is 5280360
synonyms found at PubChem are:
Prostaglandin E2, Dinoprostone, PGE2, 363-24-6, Prostin E2, Prepidil, Cervidil, Propess, Minprositin E2, Minprostin E2, Dinoproston, Prostin, Prostarmon E, Dinoprostonum, (15S)-Prostaglandin E2, l-Prostaglandin E2, Dinoprostona, PGE2alpha, l-PGE2, Prostaglandin E2alpha, Prepidil Gel, PGE2 alpha, Dinoprostonum [INN-Latin], Dinoprostona [INN-Spanish], U-12062, Prostaglandin E2 alpha, Prostaglandin E, Prostin E, Prostarmon E2, UNII-K7Q1JQR04M, Cervidil (TN), Prepidil (TN), (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, NSC 165560, [3H]PGE2, (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid, U 12062, Prostin E2 (TN), [3H]prostaglandin E2, Dinoprostone [USAN:INN:BAN:JAN], EINECS 206-656-6, CHEMBL548, NSC 196514, K7Q1JQR04M, 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid, l-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid, Dinoprostone Prostaglandin E2, Dinoprostone (JAN/USP/INN), (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid, BML1-F07, CHEBI:15551, XEYBRNLFEZDVAW-ARSRFYASSA-N, (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, l-, Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11alpha,13E,15S)-, Prostaglandin E(2), BMS-279654 & PGE2, Dinoprostone beta-Cyclodextrin Clathrate, NCGC00092361-05, (-)-Prostaglandin E2, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate, Prostaglandin E2.alpha., (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate, (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic, (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, DSSTox_CID_2947, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-, DSSTox_RID_76801, DSSTox_GSID_22947, (Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid, (Z)-7-[(1r,2r,3r)-3-Hydroxy-2-[(E,3s)-3-Hydroxyoct-1-Enyl]-5-Oxo-Cyclopentyl]hept-5-Enoic Acid, 9-oxo-11R,15S-dihydroxy-5Z,13E-prostadienoic acid, Cerviprime, Prostenone, Enzaprost E, (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, 7-[3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-5-heptenoic acid, Gel, Prepidil, Prosta-5,13-dien-1-oic acid, (5Z,11-alpha,13E,15S)-11,15-dihydroxy-9-oxo-, E2, Prostaglandin, CAS-363-24-6, Prostaglandin,PGE2, alpha, PGE2, U,062, E2alpha, Prostaglandin, SR-05000001459, alpha, Prostaglandin E2, E2 alpha, Prostaglandin, primiprost, (5Z,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid, Prosta-5, (5Z,11.alpha.,13E,15S)-11,15-dihydroxy-9-oxo-, Prosta-5, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, Prosta-5, 11,5-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, [3H]dinoprostone, 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, prosta-glandin e2, NCGC00092361-06, (E,2R,3R)-7-[3-hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid, Prestwick_793, Propess (TN), [3H]prostin E2, AC1NQWXW, Dinoprostone [USAN:USP:INN:BAN:JAN], D06FEA, SCHEMBL25533, BSPBio_001490, GTPL1883, GTPL1916, (5Z,11|A,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, DTXSID4022947, [3H]-PGE2, BDBM35847, MolPort-003-939-184, HMS1361K12, HMS1791K12, HMS1989K12, HMS2089D17, HMS3268J12, HMS3402K12, HMS3648F07, EX-A1773, ZINC3830713, Tox21_111196, LMFA03010003, MFCD00077861, NSC165560, NSC196514, AKOS015920228, Tox21_111196_1, AC-6098, CCG-208092, CCG-208256, CS-6932, DB00917, NSC-165560, NSC-196514, RP17686, IDI1_033960, SMP2_000056, NCGC00092361-01, NCGC00092361-02, NCGC00092361-03, NCGC00092361-04, AJ-45765, AN-10387, BC219642, BR-72815, HY-101952, LS-125823, B7005, P1884, 1798-EP2272832A1, 1798-EP2277848A1, 1798-EP2277858A1, 1798-EP2295055A2, 1798-EP2298767A1, 1798-EP2301922A1, 1798-EP2305641A1, 1798-EP2305653A1, 1798-EP2308510A1, 1798-EP2308872A1, 1798-EP2311453A1, 1798-EP2311808A1, 1798-EP2311829A1, 1798-EP2314574A1, 1798-EP2314587A1, 1798-EP2316829A1, C00584, D00079, Prostaglandin E2, >=93% (HPLC), synthetic, 363P246, SR-01000946417, J-502620, SR-01000946417-1, SR-05000001459-1, SR-05000001459-3, SR-05000001459-4, U-12,062, BRD-K26521938-001-04-9, 05D31BD5-818B-4A92-8CFC-BEC19926A5B3, Dinoprostone, European Pharmacopoeia (EP) Reference Standard, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoic acid, (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoate, Dinoprostone, United States Pharmacopeia (USP) Reference Standard, (5Z,11?,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1oic acid, (5Z,11I+/-,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid, (5Z,13E,15S)-11-alpha,15-dihydroxy-9-oxoprost-5,13-dienoic acid, Prostaglandin E2, synthetic, powder, BioReagent, suitable for cell culture, 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)- (8CI), 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI), Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11.alpha.,13E,15S)-, Prostaglandin E2, gamma-irradiated, powder, BioXtra, suitable for cell culture, P2E